Paul Corn
Overview
Explore the profile of Paul Corn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Laccetti A, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, et al.
Cancer Med
. 2021 Mar;
10(7):2341-2349.
PMID: 33650321
Introduction: Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and post-front-line...
12.
Surasi D, Lu Y, Corn P, Pettaway C, Bathala T
Clin Nucl Med
. 2020 Nov;
46(2):e114-e115.
PMID: 33156041
18F-Fluciclovine PET/CT has become a common diagnostic imaging study used in the evaluation of biochemical recurrence in prostate cancer since its approval in 2016. We present a case report of...
13.
Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell M, Tidwell R, et al.
Nat Med
. 2020 Oct;
26(12):1845-1851.
PMID: 33046869
Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma, with one study reporting data in cisplatin-ineligible patients who received anti-PD-L1 monotherapy. The study...
14.
Malihi P, Graf R, Rodriguez A, Ramesh N, Lee J, Sutton R, et al.
Clin Cancer Res
. 2020 Apr;
26(15):4143-4153.
PMID: 32341031
Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) , and ....
15.
Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, et al.
Cancers (Basel)
. 2020 Jan;
12(1).
PMID: 31963871
The overall goal of this study was to elucidate the role of FGFR1 induction in acquired resistance to MET and VEGFR2 inhibition by cabozantinib in prostate cancer (PCa) and leverage...
16.
Tang C, Hoffman K, Allen P, Gabel M, Schreiber D, Choi S, et al.
Cancer
. 2019 Nov;
126(3):506-514.
PMID: 31742674
Background: The purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic...
17.
Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, et al.
Eur Urol Oncol
. 2019 Aug;
3(1):119-127.
PMID: 31412017
Background: It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops...
18.
Matrana M, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, et al.
Clin Genitourin Cancer
. 2016 Aug;
15(2):e205-e208.
PMID: 27568124
Background: Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in...
19.
Matrana M, Bathala T, Campbell M, Duran C, Shetty A, Teegavarapu P, et al.
BJU Int
. 2015 Nov;
118(2):264-71.
PMID: 26573089
Objective: To explore the efficacy and safety of pazopanib in a 'real-world' setting in unselected patients, as data regarding unselected patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with...
20.
Aparicio A, Shen L, Tapia E, Lu J, Chen H, Zhang J, et al.
Clin Cancer Res
. 2015 Nov;
22(6):1520-30.
PMID: 26546618
Purpose: Morphologically heterogeneous prostate cancers that behave clinically like small-cell prostate cancers (SCPC) share their chemotherapy responsiveness. We asked whether these clinically defined, morphologically diverse, "aggressive variant prostate cancer (AVPC)"...